// STATE LEGISLATION TRACKER

Ohio HB 388: Regards state employee reimbursement for GLP-1 drug costs

⚖️ MIXED for peptide users 👤 MEDIUM user impact 📜 Status: In committee

State: Ohio
Bill: HB 388
Session: 136
Filed: 2025-07-01
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Ohio HB388 would create a reimbursement program for Ohio state employees and elected state officials who pay out of pocket for certain FDA-approved GLP-1 weight-management drugs. It is relevant to peptide users because it supports access to branded GLP-1 drugs but expressly excludes compounded GLP-1 versions.

Key Points

Applies only to Ohio state employees and elected state officials
Covers FDA-approved GLP-1 drugs for chronic weight management
Compounded GLP-1 drugs are excluded from reimbursement
Requires BMI of at least 30 as determined by a physician
Reimbursement is capped and time-limited

What to Watch For

✓

Opportunity Could lower out-of-pocket costs for eligible Ohio state employees using branded GLP-1 drugs.

Concern Compounded GLP-1 users would not benefit, which may push policy preference toward branded products.

Concern Physician-only BMI proof may leave out NP- or naturopath-led care pathways unless rules later clarify.

Note The bill does not appear to change telehealth, prescribing authority, controlled substances, PDMP, or 503A/503B rules.

Where the Bill Stands

The bill has been introduced and referred to the House General Government Committee, with no chamber passage yet.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-06 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws